Founded in 2021 and headquartered in Yokne'am Illit, Israel, Infiniplex is dedicated to making cancer screenings more accessible and affordable by integrating genomic testing into routine blood work. By identifying genetic tumor biomarkers through standard and cost-effective blood tests, the startup aims to detect both common and rare cancer types early. This innovative approach leverages existing laboratory infrastructure and expertise to provide preemptive, preventive, and follow-up screenings as part of regular health checkups.
The last investment, a Seed Round investment took place on 31 May 2022, and was carried out by Terra Venture Partners.
Specializing in the Biotechnology industry, Infiniplex is poised to revolutionize cancer detection, offering a promising opportunity for future growth and impact.
